Table 2.
Clinical, laboratory characteristics and treatment information for SARS-CoV-2 positive patients.
| All patients (n = 55) | ICU Admission (n = 15) | Supplemental O2 (n = 25) Ψ | |
|---|---|---|---|
| Patient reported clinical symptoms at baseline (no.; %) | |||
| Fever >38°C | 26; 47.3% | 9; 60.0% | 14; 56.0% |
| Malaise/myalgia | 32; 58.2% | 8; 53.3% | 14; 56.0% |
| Dyspnea | 42; 76.4% | 14; 93.3% | 22; 88.0% |
| Cough | 36; 65.5% | 9; 60.0% | 15; 60.0% |
| Coryza | 9; 16.4% | 2; 13.3% | 1; 4.0% |
| Sore throat | 16; 29.1% | 2; 13.3% | 2; 8.0% |
| Diarrhea | 16; 29.1% | 4; 26.7% | 7; 28.0% |
| Other | Headache (3; 0.05%) | Headache (0; 0%) | Headache (0; 0%) |
| Nausea and Vomiting | Nausea and Vomiting | Nausea and Vomiting | |
| (2; 0.04%) | (0; 0%) | (1; 0.04%) | |
| Pleuritic chest pain | Pleuritic chest pain | Pleuritic chest pain | |
| (4; 0.07%) | (0; 0%) | (1; 0.04%) | |
| Vital signs – baseline at hospital admission (median, IQR) | |||
| Temperature (°C) | 37.8 (36.7; 38.5) | 38.1 (37.1; 38.7) | 38.3 (37.3; 38.8) |
| Respiratory rate | 22 (20; 30) | 35 (22; 38) | 28 (22; 35) |
| Oxygen saturation (%) | 95 (92; 98) | 94 (90; 96) | 92 (90; 94) |
| Pulse rate | 96 (88; 106) | 100 (92; 119) | 100 (88; 115) |
| Blood pressure (mmHg) | 118/72 (107/66; 130/81) |
118/78 (100/60; 130/85) |
120/69 (103/64; 130/80) |
| Laboratory Data – baseline (median, IQR) | |||
| WCC (x109/L) | 6 (4.4;8) | 7.2 (4.4;8) | 7.1 (4.3;8) |
| Lymphocytes (x109/L) | 0.8 (0.7; 1.1) | 0.7 (0.5; 0.8) | 0.8 (0.6; 1) |
| Neutrophils (x109/L) | 4.3 (2.9; 6) | 5.8 (2.9; 6.6) | 5.1 (2.9; 6.2) |
| Eosinophils (x109/L) | 0 (0;0) | 0 (0;0) | 0 (0;0) |
| Hemoglobin (g/L) | 135 (123;146) | 139 (125:145) | 139 (127;145) |
| Platelet count (x109/L) | 202 (171;257) | 194 (161;253) | 194 (161;253) |
| Creatinine (μmol/L) | 74 (60; 94) | 82 (64; 95) | 82 (69; 104) |
| Estimated GFR ♦ | 90 (71;90) | 86 (71;90) | 79 (64;90) |
| Sodium (mmol/L) | 139 (136;141) | 138 (135;141) | 139 (136;141) |
| Potassium (mmol/L) | 4.1 (3.9;4.4); N=53 | 4 (4;4.4); N=13 | 4.1 (4;4.5); N=23 |
| Bicarbonate (mmol/L) | 25 (22; 27) | 25 (24;27) | 25 (24;27) |
| IL-6 (pg/ml) | 73.9 (30.9;126.39) | 56.6 (21.3;108.3) | 73.9 (31.1;123.2) |
| CRP (mg/L) | 65 (19.4; 135); N=53 | 135 (49.1; 223); N=15 | 113 (44.9; 196.5); N=24 |
| Ferritin (μg/L) | 438 (167; 864); N=50 | 1,084 (490; 1,570); N=15 | 645.5 (209; 1,311); N=24 |
| D-dimer (mg/L) | 635 (473; 972); N=53 | 1,394 (738; 2,505); N=15 | 969 (680; 1,542); N=25 |
| LDH (U/L) | 278 (236; 366); N=33 | 402.5 (326; 525); N=10 | 363 (267; 525); N=15 |
| Bilirubin (μmol/L) | 8 (6.5;13); N=48 | 10 (7;15); N=13 | 8 (6;15); N=22 |
| ALT (U/L) | 28 (21;50); N=50 | 37 (21; 49); N=14 | 28.5 (20;47); N=24 |
| AST (U/L) | 65 (55;85); N=13 | 66 (55;189); N=3 | 62.5 (55;66); N=6 |
| GGT (U/L) | 42 (25;82) | 63 (40;109) | 55 (38;84) |
| Albumin (g/L) | 35 (31; 37); N=53 | 31 (26; 36); N=15 | 32.5 (30; 36); N=24 |
| Treatment (no.; %) | |||
| Mechanical ventilation | 5 (9.1%) | 5 (33.3%) | 5 (20%) |
| Dexamethasone | 28 (50.9%) | 12 (80%) | 22 (88%) |
| Remdesivir and dexamethasone | 15 (27.3%) | 8 (53.5%) | 13 (52%) |
| Intravenous antibiotics | 35 (63.6%) | 15 (100%) | 22 (88%) |
| Antifungals | 3 (5.5%) | 3 (20%) | 3 (12%) |
ALT, alanine aminotransferase; AST, aspartate transaminase; CRP, C-Reactive protein; GFR, glomerular filtration rate; GGT, gamma-glutamyl transferase; ICU, intensive care unit; IL-6, Interleukin-6; LDH, lactate dehydrogenase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SpO2, oxygen saturation; WCC, white cell count.
Ψ Patients that required supplemental O2 continuously for more than 24 hours during their admission.
♦ Estimated GFR was calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), units: ml/min/1.73.